New Korean Fund Aims For Stem Cell, Gene Therapy Edge
This article was originally published in PharmAsia News
As some local biosimilar firms such as Celltrion have already got their feet firmly on the ground, the South Korean government is now shifting its strategic focus to support for stem cell and gene therapy ventures to help them advance into a global market where no clear leader has yet emerged.
You may also be interested in...
SEOUL - The Korean government has set up an inter-ministry team to support local pharmaceutical companies develop globally competitive drugs. The team will offer R&D training for companies looking to diversify their generic pipelines with innovative products as well as some of the start-up cash needed for new R&D programs
Court's Suspended Prison Sentence Brings Disgraced Korean Cloning Researcher A Step Closer To Return To Life Of Science
SEOUL - A Seoul court's two-year suspended prison sentence for disgraced cloning scientist Hwang Woo-Suk appears to be paving the way for a comeback to research in stem cells and human cloning
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.